Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 …
Press Release
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Access the Akari CEO Corner here TAMPA, FL and LONDON – January 9, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics to Present at the 2026 Biotech Showcase
In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, …
[Read more...] about Akari Therapeutics to Present at the 2026 Biotech Showcase
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug …
[Read more...] about Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner with Industry Leader WuXi XDC For This Key IND-enabling Work Tampa, FL and London – December 23, 2025 – Akari …
